Amphastar Misses Earnings, Stock Plunges

Amphastar Pharmaceuticals missed Wall Streets targets in Q1 2026, with revenue at $171.2M (flat YoY) vs. expected $173.1M and EPS at $0.42 vs. forecasted $0.71. Adjusted operating income fell to $22.9M from expected $43.81M, with margins shrinking to 13.4% from over 30% in recent years. The stock plunged 8.3% post-earnings, closing at $22.04, with a market cap of $1.06B. Despite recent quarters showing demand cooling off, Amphastar has strong long-term EPS growth at 31.7% thanks to buybacks and leverage. The company needs to rebound on margins and growth to keep shareholders engaged. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1b1de4c06efacd89